Archives202520242023202220212020201920182017201620152014201320122011 September 01, 2025Appointments of Chief Scientific Officer and Head of R&D Read More September 01, 2025ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases Read More August 20, 2025TR1 from Lanstead Capital – Major interest in shares Read More August 06, 2025INTERIM RESULTS for the six months ended 30 June 2025 Read More June 12, 20252025 Result of Annual General Meeting Read More May 28, 2025TR1 from Lanstead – Major interest in shares Read More May 20, 2025Notice of AGM and Annual Report & Accounts Read More May 19, 2025FINAL RESULTS for the twelve months ended 31 December 2024 Read More April 01, 2025Extension of Warrants in Incanthera to 30 September 2025 Read More March 14, 2025ImmuPharma Attending Bio-Europe Spring – 17-19 March 2025, Milan Read More March 13, 2025ImmuPharma proves unique Mechanism of Action of P140 Read More February 22, 2025TR1 from Lanstead – Major interest in shares Read More 123…16
September 01, 2025ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases Read More
